Introduction
============

Treatments for esophageal cancer have been studied intensively in recent decades. However, the clinical outcomes remain unsatisfactory, with 5-year survival rates of 49.3% for localized disease and 2.8% for metastatic disease \[[@b1-crt-2015-018]\]. Until recently, the standard treatment for early or locally advanced esophageal cancer was surgery. However, definitive chemoradiotherapy (CRT) is another possibility in cases where surgery is not an option due to advanced-stage disease or the presence of comorbidities \[[@b2-crt-2015-018]\]. To enhance the efficacy of CRT, clinical trials of various drugs have been conducted, including trials for cisplatin and 5-fluorouracil (5-FU), as well as docetaxel \[[@b3-crt-2015-018]\], paclitaxel \[[@b4-crt-2015-018]\], and cetuximab \[[@b5-crt-2015-018]\].

In addition, many recent studies have focused on identification of new biomarkers to help in prediction of the outcome after CRT and to find additional therapeutic targets. Although the underlying pathogenic mechanisms of lung cancer, colorectal cancer, and breast cancer have been investigated extensively and targeted therapies have since been developed, relatively little is known about esophageal cancer.

Esophageal cancer can metastasize readily, even at early disease stages, due to the absence of a serosa and a rich lymphatic system adjacent to the major organ, resulting in a tendency for metastasis and poor outcomes. Thus, to control the development of esophageal cancer, it is important to not only kill the tumor cells but also to inhibit invasion and metastasis. Recently, exploiting the relationship between tumor cells and the stroma was highlighted as a possible way to prevent the initiation and progression of tumors.

Fibroblasts play an important role in the tumor microenvironment. Carcinoma-associated fibroblasts in the tumor microenvironment influence tumor cell survival, growth, angiogenesis, invasion, inflammation, migration, and metastasis \[[@b6-crt-2015-018]\]. Fibroblast growth factors (FGFs) are divided into four groups (FGF1-4), and dysregulation of their receptors (FGFRs) plays an important role in tumorigenesis. Our understanding of the biological properties of FGFRs is increasing, and several reports have described their roles in cancer progression and drug sensitivity \[[@b7-crt-2015-018],[@b8-crt-2015-018]\]. Among them, FGFR4 is expressed in myofibroblasts during regeneration following injury, but not in mature skeletal muscle. An *FGFR4* Gly388Arg polymorphism (rs351855), which causes the substitution of arginine for glycine (*FGFR4* Arg388) in the transmembrane domain of the receptor, was reported to increase cancer risk \[[@b9-crt-2015-018]\], aggressiveness, metastasis \[[@b10-crt-2015-018]\], and drug resistance \[[@b11-crt-2015-018]\]. Ansell et al. \[[@b12-crt-2015-018]\] recently reported a significantly increased risk of head and neck squamous cell carcinoma (HNSCC) with the *FGFR4* Gly388 allele, whereas Arg388 resulted in cisplatin sensitivity (p=0.141) in an *in vitro* assay. In addition, Arg388 carriers showed significantly poor survival outcome in head and neck or lung cancer patients \[[@b10-crt-2015-018],[@b13-crt-2015-018]\]. Considering the similar causal factors such as alcohol or smoking and treatment modality of head and neck, lung or esophageal cancer, *FGFR4* polymorphism could be a targetable prognostic marker in esophageal cancer, for which there has been no reliable biomarker until now.

Thus, we investigated the role of *FGFR4* polymorphisms in esophageal squamous cell carcinoma patients who were treated with CRT.

Materials and Methods
=====================

1. Patients and treatment
-------------------------

This retrospective study was conducted to assess the relationship between *FGFR4* polymorphisms and treatment outcomes in patients receiving CRT for esophageal squamous cell carcinoma. The inclusion criteria were (1) a diagnosis of squamous esophageal carcinoma, (2) treatment with concurrent CRT as a preoperative or curative-aim first-line therapy with at least 4,000 cGy of radiation, (3) evaluation of the response after CRT, (4) a Karnofsky performance status ≥ 70 at diagnosis, (5) preserved organ function sufficient to receive CRT, and (6) a blood sample available for DNA analysis. Patients were excluded for (1) other confirmed or suspected malignancies, (2) types of cancer other than squamous cell carcinoma (e.g., adenocarcinoma), (3) gastroesophageal junction carcinoma, and (4) postoperative CRT.

During radiotherapy, the patients received combination chemotherapy with 5-FU (1,000 mg/m^2^ on days 1-4) and cisplatin (75 mg/m^2^ on day 1) every 4 weeks or weekly docetaxel (30 mg/m^2^ on days 1 and 8) and cisplatin (30 mg/m^2^ on days 1 and 8) every 3 weeks. Blood samples for genotyping were drawn before the start of CRT.

Evaluation of the response was based on the Response Evaluation Criteria in Solid Tumors (RECIST ver. 1.1), and was assessed 8 weeks after completion of CRT. After CRT, surgery was performed for the preoperative CRT cases. Additional chemotherapy was performed in cases where any disease remained without progression, or if surgery was not possible. Second-line chemotherapy was administered in cases where the disease had progressed.

Blood samples for polymorphism study were provided by the Chonnam National University Hwasun Hospital National Biobank of Korea, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. The study protocol was approved by the Institutional Review Board of Chonnam National University Hwasun Hospital (CNUHH-2014-016).

2. Genotyping
-------------

Genomic DNA was extracted from peripheral blood using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA), according to the manufacturer's protocol. *FGFR4* Gly388Arg genotyping was performed using high-resolution melting (HRM) analysis with a Rotor Gene 6000 (Corbett Research, Sydney, Australia). The primers were as follows: forward, 5\'-ggagagcttctgcacagtgg-3\'; and reverse, 5\'-cttggctgtgctcctgct-3\'. The reaction mixture for HRM included 200 nM polymerase chain reaction primers, 1 μM SYTO 9 fluorescent dye (Invitrogen, Carlsbad, CA), 0.5 U of f-Taq polymerase, and 40 ng of genomic DNA in 10-μL reaction volumes. The cycling conditions included an initial 5-minute hold at 95°C, followed by 40 cycles at 95°C for 5 seconds, 65°C for 30 seconds, and 72°C for 20 seconds, with an increase in the melting temperature from 78°C to 92°C at 0.1°C/sec. The genotyping results were validated using direct sequencing (ABI PRISM 3100 Genetic Analyzer, Life Technologies, Carlsbad, CA) of 16 subjects (6%), and the results showed 100% concordant. Appropriate positive/negative and internal controls were included.

3. Statistical analyses
-----------------------

The progression-free survival (PFS) time was calculated from the start of CRT to the appearance of disease progression or recurrence after surgery. The overall survival (OS) time was calculated from the start of CRT to death from any cause; patients who were alive at the last follow-up were recorded at that time. Chi-square tests were used to evaluate associations between genotypes and clinicopathological characteristics and chemotherapy responses. The Cox proportional hazards model was used to evaluate the effect of variables on OS and PFS, and to produce survival curves. The proportional hazards assumption was assessed by graphical evaluation of log-log plots. All statistical analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL). A p-value of \< 0.05 was considered to indicate statistical significance.

Results
=======

1. Study population
-------------------

Between May 2004 and December 2012, 264 patients were treated for esophageal cancer using CRT, and 244 patients suitable for inclusion were analyzed in this study. The median dose of radiation was 5,400 cGy (range, 4,000 to 6,600 cGy); 187 patients (77%) received radiation doses ≥ 5,000 cGy, and 57 (23%) received doses \< 5,000 cGy due to preoperative aims or poor general conditions.

The chemotherapy regimens during radiation treatment were as follows: 5-FU and cisplatin in 204 (84%) and docetaxel and cisplatin in 40 patients (16%). After CRT, 58 patients (24%) underwent surgery with a curative aim. In total, 143 patients (58.6%) showed disease progression after CRT or surgery, and 88 patients (36%) received second-line chemotherapy ([Table 1](#t1-crt-2015-018){ref-type="table"}).

2. Chemotherapy responses and survival
--------------------------------------

Fifty-two patients (21%; 95% confidence interval \[CI\], 16 to 27) showed a complete response, and 158 patients (65%; 95% CI, 58 to 70) showed a partial response after CRT.

Patients at an earlier stage of disease showed a significantly better response. The chemotherapy regimen during radiation therapy (5-FU+cisplatin vs. docetaxel+cisplatin) had no effect on the overall response rate (p=0.307). The median OS and PFS for stage I disease were not reached in this analysis. The median OS for stages II, III, and IV were 44.0 months (95% CI, 22.6 to 46.2), 25.6 months (95% CI, 14.0 to 32.6), and 21.9 months (95% CI, 11.3 to 27.3), respectively, and statistically significant differences were observed among the stages (p=0.001). The median PFS rates of stages II, III, and IV were also significantly different at 42.0 months (95% CI, 0.8 to 54.8), 12.7 months (95% CI, 10.0 to 15.6), and 9.3 months (95% CI, 12.1 to 16.9), respectively (p \< 0.001). These results were similar after grouping as early-stage (stages I and II) versus advanced-stage (stages III and IV) disease in PFS (p \< 0.001) and OS (p=0.001). Although 58 patients (23.7%) underwent surgery after CRT, no significant difference in survival was observed between those who underwent surgery (PFS, 17.3 months; 95% CI, 5.4 to 29.2 and OS, 30.2 months; 95% CI, 15.5 to 44.9) and those who did not (PFS, 13.6 months; 95% CI, 10.6 to 16.6; p=0.293 and OS, 24.3 months; 95% CI, 18.5 to 30.1; p=0.434).

3. *FGFR4* genotype and treatment outcome
-----------------------------------------

The frequencies of the *FGFR4* Gly388Arg polymorphic genotypes were as follows: 94 patients (38.5%) had the Gly388 allele (G/G), 110 (45.4%) were heterozygous for G/A, and 40 (16.4%) had the Arg388 allele (A/A). Patients with the G/G allele (91.5%; 95% CI, 82.9 to 95.6) showed significantly better responses to CRT than Arg carriers (82.7%; 95% CI, 75.4 to 88.0; p=0.038) ([Table 2](#t2-crt-2015-018){ref-type="table"}). However, no significant association was found between the *FGFR4* genotype and any clinicopathological parameter examined, including tumor stage, differentiation, and tumor location ([Table 1](#t1-crt-2015-018){ref-type="table"}). No difference between heterozygous and homozygous Arg388 carriers was observed in this study.

In survival analyses, no significant difference in OS or PFS was observed among genotypes. For comprehensive evaluation of the role of genotype in treatment outcome, the patients were divided into early (stages I and II; n=65) and advanced stage groups (stages III and IV; n=179). In the early stages, patients with the Gly388 allele tended to have somewhat better PFS (unreached median OS \[mOS\] in G/G, 38 months in Arg388 carriers; 95% CI, 11.9 to 63.9; p=0.506) and OS rates (unreached mOS in G/G, 45 months; 95% CI, 26.1 to 63.5; p=0.773) ([Fig. 1A](#f1-crt-2015-018){ref-type="fig"} and [C](#f1-crt-2015-018){ref-type="fig"}) than the Arg388 carriers. However, patients with advanced stage disease showed similar patterns of PFS (9.6 months in G/G; 95% CI, 6.1 to 13 and 12.6 months in Arg388 carriers; 95% CI, 10.2 to 14.9; p=0.678) and OS (24.7 months in G/G; 95% CI, 19.5 to 29.90 and 22.4 months in Arg388 carriers, 95% CI, 15.3 to 29.5; p=0.668) ([Fig. 1B](#f1-crt-2015-018){ref-type="fig"} and [D](#f1-crt-2015-018){ref-type="fig"}) regardless of genotype. In particular, patients with the Gly388 allele showed a significantly better OS rate than Arg388 carriers in the lymph node (LN) metastasis group (p=0.042) compared to the no LN metastasis group (p=0.125) ([Fig. 2](#f2-crt-2015-018){ref-type="fig"}) in the early stages.

4. Univariate and multivariate analyses
---------------------------------------

To explore the prognostic factors for esophageal cancer patients, a univariate analysis was performed with clinicopathologic variables and genotypes. A multivariate analysis using the Cox proportional hazards model was used for evaluation of the statistically significant variables found in the univariate analysis. As shown in [Table 3](#t3-crt-2015-018){ref-type="table"}, age \> 60 years, early-stage disease, and positive responder status (showing a complete or partial response) were significantly favorable prognostic factors for PFS, as were female sex, early-stage disease, and positive responder status for OS in the univariate analysis. Among these factors, stage and responder status were significant prognostic factors for survival in the multivariate analysis.

Discussion
==========

Treatment outcomes for various cancers have improved over recent decades. This can be attributed largely to the use of new chemotherapeutic agents, as well as enhanced technologies for surgery and radiation therapy. However, despite development of more drugs that target tumor cells, many obstacles to successful treatment remain. Accurate control of tumor cells and the tumor microenvironment is important in eradicating cancer. Based on this rationale, FGFRs have been identified as potential therapeutic targets known to be associated with drug resistance. Although FGFR1-3 has been extensively investigated \[[@b14-crt-2015-018]-[@b16-crt-2015-018]\], the role of FGFR4 and its potential as a therapeutic target is less understood. FGFR4 is overexpressed in human prostate, breast, colon, rhabdomyosarcoma, gastric, and hepatocellular cancers, where it may be associated with tumor progression and invasion via a variety of pathways, and with a poor prognosis \[[@b17-crt-2015-018],[@b18-crt-2015-018]\]. Recent studies found that *FGFR4* promotes the epithelialmesenchymal transition (EMT) in cancer cells \[[@b19-crt-2015-018],[@b20-crt-2015-018]\].

Studies of *FGFR* polymorphisms have reported association of Arg388 with increased cancer incidence, tumor size \[[@b17-crt-2015-018],[@b21-crt-2015-018]\], and recurrence after adjuvant treatment \[[@b11-crt-2015-018],[@b12-crt-2015-018],[@b22-crt-2015-018]\]. In addition, FGFR affects radiation therapy outcomes. The current study was conducted in order to assess the role of *FGFR4* Arg388 in patients treated with CRT for esophageal cancer, which is treated primarily by CRT in inoperable cases. We found that patients with the Gly388 allele showed a significantly better response to CRT than Arg388 carriers, regardless of the cancer stage. Interestingly, the PFS and OS rates in early esophageal cancer (stages I and II) showed improved survival trends with the Gly388 versus the Arg388 allele. However, comparable patterns of PFS and OS in advanced esophageal cancer (stages III and IV) were observed between the groups.

In the study reported by Thussbas et al. \[[@b11-crt-2015-018]\] in breast cancer patients, disease-free survival with the Gly388 allele was prolonged significantly compared with the Arg388 allele when patients received adjuvant chemotherapy; however, no difference was observed among patients who underwent adjuvant endocrine therapy. Thus, FGFR4 could be involved in efficacy of chemotherapy, but not endocrine therapy. The current study suggests that FGFR4 affects the response to chemotherapy and adjuvant therapy outcomes. A possible mechanism that would fit this result is the EMT, an important step in disease recurrence after surgery \[[@b23-crt-2015-018]\]. In a previous report, FGFR4 was shown to participate in a complex with membrane-type 1 matrix metalloproteinase (MT1-MMP), decreasing MT1-MMP lysosomal degradation and leading to increased invasion. In the current study, we extended the focus by assessing the functional role of FGFR4 according to stage. Although the difference was not statistically significant, the pattern of survival differed according to stage, showing a tendency to be prolonged in Gly388 versus Arg388 carriers. In addition, in early esophageal cancer patients with LN invasion, significantly improved OS was observed in patients with the Gly388 allele compared to Arg388 carriers. However, this result was not observed in patients receiving palliative care for advanced-stage disease. Progression in advanced tumors is more complex than in early stage tumors through the activation of mesenchymal and epithelial signaling pathways. Thus the function of a single gene can be difficult to assess during treatment in advanced cancer. Taken together, the current data suggest that targeted therapy for FGFR4 could be more effective at earlier rather than more advanced stages of esophageal cancer, and that another treatment approach is needed for patients carrying Arg388 in order to improve the treatment outcome. Unexpectedly, a better trend of OS was observed in Gly388 with LN invasion patients compared to Gly388 without LN invasion patients. Further study with a large number of patients will be needed in order to provide additional evidence to support this result.

FGFs play important roles in the tumor microenvironment, where there is a protective niche for therapeutic escape, through the secretion of various growth factors \[[@b6-crt-2015-018]\]. The molecular mechanism by which the *FGFR4* Arg388 polymorphism leads to a more aggressive clinical phenotype is not yet fully understood. In a colorectal cancer model, Heinzle et al. \[[@b21-crt-2015-018]\] showed that the *FGFR4* Arg388 polymorphism induced overexpression of FGFR and that this could attenuate the response to chemotherapy \[[@b22-crt-2015-018]\]. A similar result was reported in a gastric cancer model showing that an FGFR4 inhibitor and 5-FU reduced proliferation and promoted apoptosis \[[@b24-crt-2015-018]\]. For HNSCC, the association between CRT and FGFR4 was evaluated *in vitro*, showing increased sensitivity of cells containing the Arg388 allele to cisplatin, which differs from our observations \[[@b12-crt-2015-018]\].

In contrast to various results primarily from *in vitro* studies, there is a lack of clear evidence for any relationship between the *FGFR4* Arg388 genotype and protein expression or clinicopathological parameters in cancer patients \[[@b11-crt-2015-018],[@b18-crt-2015-018]\] However, the *FGFR4* Gly388 allele has been reported as a prognostic marker for survival in breast and gastric cancer patients. The lack of correlation between genotype and phenotype for FGFR4 may be explained in part by the lack of elevated tyrosine phosphorylation of *FGFR4* Arg388 compared with *FGFR4* Gly388, the use of different intracellular signal transduction pathway(s) or interactions with different cell surface protein(s), or linkage disequilibrium with other genetic changes that also contribute to a poor prognosis \[[@b11-crt-2015-018]\]. To the best of our knowledge, this is the first report describing a predictive role for *FGFR4* Arg388 after CRT. The biochemical effects of *FGFR4* Arg388 with regard to chemotherapy should be evaluated in future studies including other biomarkers.

Based on our results, clinical factors including early-stage disease and chemotherapy responders were favorable prognostic factors for PFS and OS in a multivariate analysis. Interestingly, patients \> 60 years of age had longer PFS than younger patients. The proportions of TNM stages were similar between the two groups (p=0.324); thus, understanding the biology during aging may be another approach to improving treatment outcomes.

Conclusion
==========

Although the *FGFR4* polymorphism examined in this study is not a significant prognostic factor in esophageal cancer treated with CRT, esophageal cancer patients carrying *FGFR4* Gly388 showed a good response after CRT. Especially in early esophageal cancer, the Gly388 allele resulted in increased OS and PFS, and select patients showing LN invasion showed significant prolonged OS compared to Arg388 carriers. These findings support the idea that the effect of *FGFR4* on treatment outcomes after CRT differs according to stage and further prospective study is needed in order to validate these findings.
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![Association between genotype and survival outcome. In early stage of esophageal cancer, *FGFR4* Gly388 allele (G/G) patients show better trends of progression-free survival (A) and overall survival (C) than *FGFR4* Arg388 carriers (G/A or A/A) without statistical significance. However, the progression-free survival (B) and overall survival (D) in advanced stage of esophageal cancer patients show comparable outcomes regardless of genotypes.](crt-2015-018f1){#f1-crt-2015-018}

![Survival according to genotype in early esophageal cancer. In early esophageal cancer, *FGFR4* Gly388 allele patients showed a better trend of progression-free survival (A) (p=0.079) and significantly better overall survival (C) (p=0.042) than *FGFR4* Arg388 carriers in lymph node (LN)-positive patients. However, there was no difference in LN-negative patients according to genotypes (B, D).](crt-2015-018f2){#f2-crt-2015-018}

###### 

Patient clinicopathologic characteristics

                             Total        G/G          G/A          A/A          p-value   G/A or AA   p-value
  -------------------------- ------------ ------------ ------------ ------------ --------- ----------- ---------
  No. (%)                    244          94 (39)      110 (45)     40 (16)                150 (61)    
  Median age (range, yr)     66 (41-87)   64 (41-79)   66 (47-87)   66 (49-81)                         
   ≤ 60                      75 (31)      32 (34)      31 (28)      12 (30)      0.66      43 (29)     0.228
   \> 60                     169 (69)     62 (66)      79 (72)      28 (70)                107 (71)    
  Sex                                                                                                  
   Male                      237 (97)     91 (97)      106 (96)     40 (100)     0.485     146 (97)    0.549
   Female                    7 (7)        3 (3)        4 (4)        0                      4 (3)       
  Differentiation                                                                                      
   Well                      102 (42)     37 (39)      46 (42)      19 (47)      0.95      65 (43)     0.75
   Moderate                  85 (35)      32 (34)      40 (36)      13 (33)                53 (35)     
   Poorly                    32 (13)      15 (16)      13 (12)      4 (10)                 17 (12)     
   Unknown                   25 (10)      10 (11)      11 (10)      4 (10)                 15 (10)     
  Tumor location                                                                                       
   Upper                     63 (26)      27 (29)      21 (19)      15 (38)      0.123     36 (24)     0.712
   Mid                       133 (54)     49 (52)      68 (62)      16 (40)                84 (56)     
   Lower                     48 (20)      18 (19)      21 (19)      9 (23)                 30 (20)     
  TNM stage                                                                                            
   I                         11 (5)       3 (3)        7 (6)        1 (3)        0.859     8 (5)       0.839
   II                        54 (22)      21 (21)      23 (21)      11 (27)                34 (23)     
   III                       101 (41)     39 (42)      45 (41)      17 (43)                62 (41)     
   IV                        78 (32)      32 (34)      35 (32)      1 (27)                 46 (31)     
  Chemotherapy                                                                                         
   FP                        204 (84)     76 (81)      93 (85)      36 (87)      0.596     128 (85)    0.228
   DP                        40 (16)      18 (19)      17 (15)      5 (13)                 22 (15)     
  Operation                                                                                            
   Yes                       58 (24)      73 (78)      82 (74)      32 (80)      0.661     113 (75)    0.399
   No                        186 (76)     21 (22)      29 (26)      8 (20)                 37 (25)     
  Second-line chemotherapy                                                                             
   Yes                       88 (36)      58 (62)      71 (65)      27 (67)      0.802     98 (65)     0.33
   No                        156 (64)     36 (38)      39 (35)      13 (33)                52 (35)     

Values are presented as number (%) unless otherwise indicated. FP, fluoropyrimidine and cisplatin; DP, docetaxel and cisplatin.

###### 

Response after chemoradiotherapy according to *FGFR4* Gly388Arg polymorphism

  Genotype          Responder (CR+PR, n=210)   Non-responder (SD+PD, n=34)   p-value
  ----------------- -------------------------- ----------------------------- ---------
  G/G (n=94)        86 (91.5)                  8 (8.5)                       0.090
  G/A (n=110)       89 (80.9)                  21 (19.1)                     
  A/A (n=40)        35 (87.5)                  5 (12.5)                      
  G/G (n=94)        86 (91.5)                  8 (8.5)                       0.038
  G/A+A/A (n=150)   124 (82.7)                 26 (17.3)                     

Values are presented as number (% of each gene group). *FGFR4*, fibroblast growth factor receptor 4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Univariate analysis for survival

                             PFS (median, mo)   p-value    OS (median, mo)   p-value
  -------------------------- ------------------ ---------- ----------------- ----------
  Age (yr)                                                                   
   ≤ 60                      9.9±2.12           0.003      24.4±3.15         0.139
   \> 60                     21.9±4.03                                       
  Sex                                                                        
   Male                      8.1±7.10           0.472      16.3±6.10         0.044
   Female                    15.4±1.69                     33.3±6.55         
  Differentiation                                                            
   Well                      20.9±5.47          0.055      34.5±11.12        0.318
   Moderate+poorly           12.8±1.30                     23.7±4.26         
  Tumor location                                                             
   Upper                     18.3±3.64          0.28       38.3±7.94         0.279
   Middle                    14.3±3.38                     34.5±7.03         
   Lower                     12.3±2.55                     19.0±1.82         
  Clinical stage                                                             
   I-II                      NR                 \< 0.001   NR                0.001
   III-IV                    11.6±1.13                     23.5±2.29         
  CRT response                                                               
   Responder (CR+PR)         20.9±2.93          \< 0.001   38.3±4.52         \< 0.001
   Non responder (SD+PD)     6.8±1.11                      11.8±1.56         
  Operation                                                                  
   Yes                       21.7±5.97          0.239      56.7±15.49        0.14
   No                        14.3±1.43                     29.8±4.79         
  RT dose                                                                    
   Stage I-II                                                                
    ≥ 5,000 cGy              58.9±7.52          0.353      66.3±7.19         0.318
    \< 5,000 cGy             63.7±13.63                    75.8±13.29        
   Stage III-IV                                                              
    ≥ 5,000 cGy              26.8±2.81          0.426      48.3±6.66         0.415
    \< 5,000 cGy             38.2±6.38                     40.2±3.37         
  Chemoregimen                                                               
   FP                        15.0±1.66          0.637      32.4±4.57         0.664
   DP                        18.0±6.86                     34.5±9.70         
  Second-line chemotherapy                                                   
   Yes                       8.8±0.82           0.382      21.6±1.99         0.692
   No                        9.0±1.14                      17.8±2.64         
  Genotype                                                                   
   Stage I-II                                                                
    G/G                      NR                 0.506      NR                0.773
    G/A+A/A                  44.8±9.54                     37.9±13.25        
   Stage III-IV                                                              
    G/G                      9.6±1.75           0.678      24.7±2.65         0.668
    G/A+A/A                  12.5±1.22                     22.4±3.63         

PFS, progression-free survival; OS, overall survival; NR, not reached until this analysis; CRT, chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease, RT, radiotherapy; FP, 5-fluorouracil+cisplatin; DP, docetaxel+cisplatin.
